Emergent BioSolutions Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Emergent BioSolutions Inc |
Stock Symbol : | NYSE:EBS |
Class Period Start: | 01/11/2016 |
Class Period End: | 06/21/2016 |
Lead Plaintiff motion: | 09/19/2016 |
Date Filed: | 07/19/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the District of Maryland |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the September 19, 2016 lead plaintiff deadline in a class action lawsuit filed against Emergent Biosolutions Inc (NYSE:EBS) (“Emergent” or “the Company”). The suit is pending in the U.S. District Court for the District of Maryland and investors, who purchased Emergent BioSolutions Inc securities between January 11, 2016 and June 21, 2016, have until September 19, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Emergent BioSolutions Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period the Company issued materially false and misleading statements about lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. These statements caused the Company’s common stock to trade at artificially inflated prices, which certain defendants were able to sell. On June 22, 2016, Emergent revealed that the U.S. government issued notices that it would purchase less doses of BioThrax than investors were led to believe, and that when newer and faster next-generation anthrax vaccines are approved, Emergent will lose its procurement contract exclusivity with the government. Following this news, shares of the stock dropped in value. If you were negatively impacted by your investment in Emergent BioSolutions Inc securities between January 11, 2016 and June 21, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |